European public and private organisations are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.
Three new positions offering exciting challenges to qualified applicants are now available at EVI:
Institut Pasteur currently has a postdoctoral position in malaria vaccine developement. Applications should be made to Prof. Chetan Chitnis chetan [dot] chitnis [at] pasteur [dot] fr by 15 January 2016
EVI extends heartfelt thanks to all our donors, colleagues, collaborators, friends and well wishers, whose presence at this annual event, made it a truly memorable occasion.
EVI wishes you a peaceful, restful Xmas, and we hope to see you at next year's Rendez-Vous.
The full article, entitled "The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine", can be accessed via this link.
Two years after the completion of the European Commission funded, EVI co-ordinated TRANSVAC project, results are still emerging, such as the recent article in PLOS neglected tropical diseases: Deep Sequencing Analysis of the Ixodes ricinus Haemocytome
Commissioned research for European Small and Medium size Enterprises (SME) and Public Health Organizations.
The ADITEC project is looking to support SMEs and public health organizations from within or outside the ADITEC consortium in vaccine development work that will result in public health benefit. We are actively seeking research proposals clearly aimed at vaccine development, where specific support can be requested in the areas listed below. These services are offered by current ADITEC consortium partners and are available free of charge to the requesting SME or public health organization, upon approval of the proposal.
Deadline: 30 October 2015 5:00 p.m. CET
- 1 of 11